Richard E Lee

List of Publications by Year
in descending order

191	11,263	30070 54	34986 98
papers	citations	h-index	g-index

198	198	198	11695
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biophysical analysis of the Mycobacteria tuberculosis peptide binding protein DppA reveals a stringent peptide binding pocket. Tuberculosis, 2022, 132, 102157.	1.9	4
2	A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes. Journal of Medicinal Chemistry, 2022, 65, 2342-2360.	6.4	19
3	Synthesis and Structureâ€“Activity Relationship of Thioacetamide-Triazoles against Escherichia coli. Molecules, 2022, 27, 1518.	3.8	3
4	A genome-wide atlas of antibiotic susceptibility targets and pathways to tolerance. Nature Communications, 2022, 13, .	12.8	12
5	The Discovery and Development of Thienopyrimidines as Inhibitors of Helicobacter pylori That Act through Inhibition of the Respiratory Complex I. ACS Infectious Diseases, 2021, 7, 1044-1058.	3.8	6
6	Synthesis, antibacterial action, and ribosome inhibition of deoxyspectinomycins. Journal of Antibiotics, 2021, 74, 381-396.	2.0	7
7	Replacement of S14 Protein in Ribosomes of Zinc-Starved Mycobacteria Reduces Spectinamide Sensitivity. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	3
8	Combating Multidrugâ€Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling. Clinical Pharmacology and Therapeutics, 2021, 109, 1000-1020.	4.7	10
9	Evaluating and evolving a screening library in academia: the St Jude approach. Drug Discovery Today, 2021, 26, 1060-1069.	6.4	6
10	Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0174420.	3.2	7
11	Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. ACS Infectious Diseases, 2021, 7, 2850-2863.	3.8	8
12	Pantothenate kinase activation relieves coenzyme A sequestration and improves mitochondrial function in mice with propionic acidemia. Science Translational Medicine, 2021, 13, eabf5965.	12.4	12
13	17-DMAG dually inhibits Hsp90 and histone lysine demethylases in alveolar rhabdomyosarcoma. IScience, 2021, 24, 101996.	4.1	7
14	Azaindole Based Potentiator of Antibiotics against Gram-Negative Bacteria. ACS Infectious Diseases, 2021, 7, 3009-3024.	3.8	9
15	Phenylâ€Glutarimides: Alternative Cereblon Binders for the Design of PROTACs. Angewandte Chemie - International Edition, 2021, 60, 26663-26670.	13.8	45
16	Identification of Inhibitors of Fungal Fatty Acid Biosynthesis. ACS Infectious Diseases, 2021, 7, 3210-3223.	3.8	7
17	LipE guided discovery of isopropylphenyl pyridazines as pantothenate kinase modulators. Bioorganic and Medicinal Chemistry, 2021, 52, 116504.	3.0	3
18	Discovery and Characterization of the Antimetabolite Action of Thioacetamide-Linked 1,2,3-Triazoles as Disruptors of Cysteine Biosynthesis in Gram-Negative Bacteria. ACS Infectious Diseases, 2020, 6, 467-478.	3.8	15

#	Article	IF	Citations
19	Mechanisms of Resistance Associated with the Inhibition of the Dehydration Step of Type II Fatty Acid Synthase in Mycobacterium tuberculosis. ACS Infectious Diseases, 2020, 6, 195-204.	3.8	12
20	Development of BODIPY FL Thalidomide As a High-Affinity Fluorescent Probe for Cereblon in a Time-Resolved Fluorescence Resonance Energy Transfer Assay. Bioconjugate Chemistry, 2020, 31, 2564-2575.	3.6	8
21	Structural basis for substrate recognition and chemical inhibition of oncogenic MAGE ubiquitin ligases. Nature Communications, 2020, 11, 4931.	12.8	17
22	Winners of the 2019 JA ÅŒmura Awards for excellence. Journal of Antibiotics, 2020, 73, 737-738.	2.0	0
23	Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	0
24	Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer. Cancer Research, 2020, 80, 3507-3518.	0.9	28
25	Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five Î²-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae. MBio, 2020, 11, .	4.1	17
26	Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. Pharmaceutical Research, 2019, 36, 136.	3.5	19
27	Mechanistic Insight on the Mode of Action of Colletoic Acid. Journal of Medicinal Chemistry, 2019, 62, 6925-6940.	6.4	2
28	Ureadepsipeptides as ClpP Activators. ACS Infectious Diseases, 2019, 5, 1915-1925.	3.8	27
29	Winners of the 2018 JA ÅŒmura Awards for excellence. Journal of Antibiotics, 2019, 72, 783-784.	2.0	0
30	Disseminated sporotrichosis following iatrogenic immunosuppression for suspected pyoderma gangrenosum. Lancet Infectious Diseases, The, 2019, 19, e385-e391.	9.1	32
31	Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice. Tuberculosis, 2019, 114, 119-122.	1.9	8
32	Identification of Small Molecules Exhibiting Oxacillin Synergy through a Novel Assay for Inhibition of vraTSR Expression in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	10
33	Aminomethyl spectinomycins: a novel antibacterial chemotype for biothreat pathogens. Journal of Antibiotics, 2019, 72, 693-701.	2.0	9
34	De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX. Journal of Medicinal Chemistry, 2019, 62, 6377-6390.	6.4	30
35	Efficacy of Aminomethyl Spectinomycins against Complex Upper Respiratory Tract Bacterial Infections. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	4
36	Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis. European Journal of Pharmaceutical Sciences, 2019, 127, 233-239.	4.0	9

#	Article	IF	Citations
37	Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 947-951.	5.6	53
38	The Isoniazid Metabolites Hydrazine and Pyridoxal Isonicotinoyl Hydrazone Modulate Heme Biosynthesis. Toxicological Sciences, 2019, 168, 209-224.	3.1	24
39	Aminomethyl Spectinomycins as Therapeutics for Drug-Resistant Gonorrhea and Chlamydia Coinfections. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	22
40	CINPA1 binds directly to constitutive androstane receptor and inhibits its activity. Biochemical Pharmacology, 2018, 152, 211-223.	4.4	19
41	Solid-Phase Synthesis and Antibacterial Activity of Cyclohexapeptide Wollamide B Analogs. ACS Combinatorial Science, 2018, 20, 172-185.	3.8	15
42	Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 25-36.	3.0	23
43	Pharmacophore Modeling, Synthesis, and Antibacterial Evaluation of Chalcones and Derivatives. ACS Omega, 2018, 3, 18343-18360.	3.5	20
44	A therapeutic approach to pantothenate kinase associated neurodegeneration. Nature Communications, 2018, 9, 4399.	12.8	65
45	In Vivo and In Vitro Effects of a ClpP-Activating Antibiotic against Vancomycin-Resistant Enterococci. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	22
46	Exposure of Methicillin-Resistant Staphylococcus aureus to Low Levels of the Antibacterial THAM-3Î¦G Generates a Small Colony Drug-Resistant Phenotype. Scientific Reports, 2018, 8, 9850.	3.3	5
47	New Î²-lactam â€“ Tetramic acid hybrids show promising antibacterial activities. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3105-3112.	2.2	13
48	The Structural and Functional Basis for Recurring Sulfa Drug Resistance Mutations in Staphylococcus aureus Dihydropteroate Synthase. Frontiers in Microbiology, 2018, 9, 1369.	3.5	58
49	Design, synthesis and microbiological evaluation of ampicillinâ€“tetramic acid hybrid antibiotics. Journal of Antibiotics, 2017, 70, 65-72.	2.0	19
50	Use of Selective Fungal Culture Media Increases Rates of Detection of Fungi in the Respiratory Tract of Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2017, 55, 1122-1130.	3.9	48
51	Synthesis and Evaluation of Thiazolidine Amide and Nâ€Thiazolyl Amide Fluoroquinolone Derivatives. Archiv Der Pharmazie, 2017, 350, e201700029.	4.1	10
52	Fluid-Attenuated Inversion Recovery (FLAIR) Signal Intensity Can Identify Stroke Within 6 and 8 Hours. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1582-1587.	1.6	6
53	RelA Mutant Enterococcus faecium with Multiantibiotic Tolerance Arising in an Immunocompromised Host. MBio, 2017, 8, .	4.1	72
54	Structural and In Vivo Studies on Trehalose-6-Phosphate Synthase from Pathogenic Fungi Provide Insights into Its Catalytic Mechanism, Biological Necessity, and Potential for Novel Antifungal Drug Design. MBio, 2017, 8, .	4.1	26

#	Article	IF	Citations
55	Structureâ€“Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions. ACS Infectious Diseases, 2017, 3, 72-88.	3.8	36
56	A Fluorescent Probe for Detecting Mycobacterium tuberculosis and Identifying Genes Critical for Cell Entry. Frontiers in Microbiology, 2016, 7, 2021.	3.5	12
57	Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw467.	3.0	27
58	New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Advanced Drug Delivery Reviews, 2016, 102, 55-72.	13.7	269
59	A Tribute to Amy Anderson (1969â˜2016): Leader, Role Model, and Advocate for Structure-Based Design of New Antimicrobial Agents. ACS Infectious Diseases, 2016, 2, 664-665.	3.8	1
60	Pterinâ€“sulfa conjugates as dihydropteroate synthase inhibitors and antibacterial agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3950-3954.	2.2	72
61	Synthesis and antibacterial evaluation of macrocyclic diarylheptanoid derivatives. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4070-4076.	2.2	5
62	Allosteric Regulation of Mammalian Pantothenate Kinase. Journal of Biological Chemistry, 2016, 291, 22302-22314.	3.4	29
63	Translational PK/PD of anti-infective therapeutics. Drug Discovery Today: Technologies, 2016, 21-22, 41-49.	4.0	22
64	Structures of trehalose-6-phosphate phosphatase from pathogenic fungi reveal the mechanisms of substrate recognition and catalysis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7148-7153.	7.1	44
65	Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3. Antimicrobial Agents and Chemotherapy, 2016, 60, 5198-5207.	3.2	99
66	Synthesis and evaluation of colletoic acid core derivatives. European Journal of Medicinal Chemistry, 2016, 110, 126-132.	5.5	8
67	Tissue Penetration of a Novel Spectinamide Antibiotic for the Treatment of Tuberculosis. AAPS Journal, 2016, 18, 788-791.	4.4	5
68	Activation of Exogenous Fatty Acids to Acyl-Acyl Carrier Protein Cannot Bypass FabI Inhibition in Neisseria. Journal of Biological Chemistry, 2016, 291, 171-181.	3.4	21
69	Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 388-391.	2.2	26
70	Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes. Journal of Antimicrobial Chemotherapy, 2016, 71, 956-963.	3.0	5
71	Phase II metabolic pathways of spectinamide antitubercular agents: a comparative study of the reactivity of 4-substituted pyridines to glutathione conjugation. MedChemComm, 2016, 7, 114-117.	3.4	11
72	SB-224289 Antagonizes the Antifungal Mechanism of the Marine Depsipeptide Papuamide A. PLoS ONE, 2016, 11, e0154932.	2.5	21

#	Article	IF	Citations
73	Advances in Drug Discovery and Development for Pediatric Tuberculosis. Mini-Reviews in Medicinal Chemistry, 2016, 16, 481-497.	2.4	11
74	In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. Scientific Reports, 2015, 5, 13985.	3.3	41
75	Aminomethyl spectinomycins as therapeutics for drug-resistant respiratory tract and sexually transmitted bacterial infections. Science Translational Medicine, 2015, 7, 288ra75.	12.4	16
76	Covalent Modification of the Mycobacterium tuberculosis FAS-II Dehydratase by Isoxyl and Thiacetazone. ACS Infectious Diseases, 2015, 1, 91-97.	3.8	58
77	Activity-Independent Discovery of Secondary Metabolites Using Chemical Elicitation and Cheminformatic Inference. ACS Chemical Biology, 2015, 10, 2616-2623.	3.4	43
78	Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model ofClostridium difficileinfection. Journal of Antimicrobial Chemotherapy, 2015, 70, 3061-3069.	3.0	27
79	Pentacyclic Nitrofurans with In Vivo Efficacy and Activity against Nonreplicating Mycobacterium tuberculosis. PLoS ONE, 2014, 9, e87909.	2.5	24
80	A Screen for and Validation of Prodrug Antimicrobials. Antimicrobial Agents and Chemotherapy, 2014, 58, 1410-1419.	3.2	27
81	In Vitro and In Vivo Activities of HPi1, a Selective Antimicrobial against Helicobacter pylori. Antimicrobial Agents and Chemotherapy, 2014, 58, 3255-3260.	3.2	9
82	False-Positive Reaction of <scp>l</scp> -Canavanine Glycine Bromothymol Blue Medium with Candida famata. Journal of Clinical Microbiology, 2014, 52, 1308-1309.	3.9	1
83	Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nature Medicine, 2014, 20, 152-158.	30.7	160
84	Novel Insights into the Mechanism of Inhibition of MmpL3, a Target of Multiple Pharmacophores in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6413-6423.	3.2	174
85	Identification and Characterization of an Allosteric Inhibitory Site on Dihydropteroate Synthase. ACS Chemical Biology, 2014, 9, 1294-1302.	3.4	34
86	Development of BODIPY FL Vindoline as a Novel and High-Affinity Pregnane X Receptor Fluorescent Probe. Bioconjugate Chemistry, 2014, 25, 1664-1677.	3.6	23
87	The identification, analysis and structure-based development of novel inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase. Bioorganic and Medicinal Chemistry, 2014, 22, 2157-2165.	3.0	14
88	Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2585-2588.	2.2	9
89	Synthesis, Structureâ€“Activity Relationship Studies, and Antibacterial Evaluation of 4-Chromanones and Chalcones, as Well as Olympicin A and Derivatives. Journal of Medicinal Chemistry, 2014, 57, 8398-8420.	6.4	86
90	Chemical Modulation of the Biological Activity of Reutericyclin: a Membrane-Active Antibiotic from Lactobacillusreuteri. Scientific Reports, 2014, 4, 4721.	3.3	27

#	Article	IF	Citations
91	Metabolic Activation of CaMKII by Coenzyme A. Molecular Cell, 2013, 52, 325-339.	9.7	35
92	Metabolic Activation of CaMKII by Coenzyme A. Molecular Cell, 2013, 52, 468.	9.7	1
93	Syntheses and evaluation of macrocyclic engelhardione analogs as antitubercular and antibacterial agents. Journal of Antibiotics, 2013, 66, 319-325.	2.0	15
94	Replacing sulfa drugs with novel DHPS inhibitors. Future Medicinal Chemistry, 2013, 5, 1331-1340.	2.3	42
95	Fragment-Based Approach Identifies a Novel Inhibitory Site on DHPS. Biophysical Journal, 2013, 104, 403a.	0.5	0
96	Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorganic and Medicinal Chemistry, 2013, 21, 2587-2599.	3.0	72
97	Pantothenamides Are Potent, On-Target Inhibitors of Plasmodium falciparum Growth When Serum Pantetheinase Is Inactivated. PLoS ONE, 2013, 8, e54974.	2.5	80
98	Potentiation of Azole Antifungals by 2-Adamantanamine. Antimicrobial Agents and Chemotherapy, 2013, 57, 3585-3592.	3.2	32
99	Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. Expert Review of Clinical Pharmacology, 2013, 6, 159-170.	3.1	19
100	The membrane as a target for controlling hypervirulent Clostridium difficile infections. Journal of Antimicrobial Chemotherapy, 2013, 68, 806-815.	3.0	31
101	New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics. Current Pharmaceutical Design, 2013, 20, 4357-4378.	1.9	84
102	Catalysis and Sulfa Drug Resistance in Dihydropteroate Synthase. Science, 2012, 335, 1110-1114.	12.6	210
103	Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. Bioorganic and Medicinal Chemistry, 2012, 20, 6063-6072.	3.0	39
104	Evaluation of Flavonoid and Resveratrol Chemical Libraries Reveals Abyssinone II as a Promising Antibacterial Lead. ChemMedChem, 2012, 7, 1541-1545.	3.2	33
105	Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nature Chemical Biology, 2012, 8, 334-341.	8.0	384
106	Acyl-sulfamates target the essential glycerol-phosphate acyltransferase (PlsY) in Gram-positive bacteria. Bioorganic and Medicinal Chemistry, 2012, 20, 4985-4994.	3.0	17
107	Structureâ€Based Design of Novel Pyrimido[4,5â€c]pyridazine Derivatives as Dihydropteroate Synthase Inhibitors with Increased Affinity. ChemMedChem, 2012, 7, 861-870.	3.2	31
108	Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability. Bioorganic and Medicinal Chemistry, 2012, 20, 3255-3262.	3.0	75

#	Article	IF	Citations
109	Development of a Pterin-Based Fluorescent Probe for Screening Dihydropteroate Synthase. Bioconjugate Chemistry, 2011, 22, 2110-2117.	3.6	9
110	Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nature Reviews Microbiology, 2011, 9, 62-75.	28.6	667
111	The structureâ€“activity relationship of urea derivatives as anti-tuberculosis agents. Bioorganic and Medicinal Chemistry, 2011, 19, 5585-5595.	3.0	100
112	Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6973-6976.	2.2	64
113	Synthesis of bi-substrate state mimics of dihydropteroate synthase as potential inhibitors and molecular probes. Bioorganic and Medicinal Chemistry, 2011, 19, 1298-1305.	3.0	17
114	Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations. Journal of Antimicrobial Chemotherapy, 2011, 66, 1773-1776.	3.0	29
115	Novel Polyoxyethylene-Containing Glycolipids Are Synthesized inCorynebacterium matruchotiiandMycobacterium smegmatisCultured in the Presence of Tween 80. Journal of Lipids, 2011, 2011, 1-12.	4.8	18
116	Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-d-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC). Bioorganic and Medicinal Chemistry, 2010, 18, 896-908.	3.0	79
117	Crystal Structure of the 6-Hydroxymethyl-7,8-Dihydropterin Pyrophosphokinaseâ€¢Dihydropteroate Synthase Bifunctional Enzyme from Francisella tularensis. PLoS ONE, 2010, 5, e14165.	2.5	26
118	Detection of Mycolactone A/B in Mycobacterium ulceransâ€“Infected Human Tissue. PLoS Neglected Tropical Diseases, 2010, 4, e577.	3.0	42
119	In vitropharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Future Medicinal Chemistry, 2010, 2, 1355-1369.	2.3	54
120	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase. Journal of Medicinal Chemistry, 2010, 53, 166-177.	6.4	81
121	Structural Characterization of the Mycobacterium tuberculosis Biotin Biosynthesis Enzymes 7,8-Diaminopelargonic Acid Synthase and Dethiobiotin Synthetase,. Biochemistry, 2010, 49, 6746-6760.	2.5	50
122	Evaluation of Analogs of Reutericyclin as Prospective Candidates for Treatment of Staphylococcal Skin Infections. Antimicrobial Agents and Chemotherapy, 2009, 53, 4028-4031.	3.2	23
123	A simple in vitro PK/PD model system to determine timeâ€“kill curves of drugs against Mycobacteria. Tuberculosis, 2009, 89, 378-385.	1.9	33
124	A statistical framework to evaluate virtual screening. BMC Bioinformatics, 2009, 10, 225.	2.6	81
125	Structureâ€Based Design, Synthesis, and Evaluation of 2â€²â€(2â€Hydroxyethyl)â€2â€²â€deoxyadenosine and the 5â€²â€Diphosphate Derivative as Ribonucleotide Reductase Inhibitors. ChemMedChem, 2009, 4, 1649-1656.	3.2	4
126	Synthesis, optimization and structureâ€“activity relationships of 3,5-disubstituted isoxazolines as new anti-tuberculosis agents. European Journal of Medicinal Chemistry, 2009, 44, 460-472.	5.5	60

#	Article	IF	Citations
127	Discovery, synthesis, and biological evaluation of piperidinol analogs with anti-tuberculosis activity. Bioorganic and Medicinal Chemistry, 2009, 17, 3588-3594.	3.0	24
128	Lipid Profiling Using Two-Dimensional Heteronuclear Single Quantum Coherence NMR. Methods in Molecular Biology, 2009, 579, 89-102.	0.9	6
129	Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase. Journal of Chemical Information and Modeling, 2009, 49, 444-460.	5.4	367
130	Novel Acyl Phosphate Mimics that Target PlsY, an Essential Acyltransferase in Gramâ€Positive Bacteria. ChemMedChem, 2008, 3, 1936-1945.	3.2	40
131	Quantitative structureâ€“activity relationship studies on nitrofuranyl anti-tubercular agents. Bioorganic and Medicinal Chemistry, 2008, 16, 8042-8053.	3.0	46
132	Design, synthesis, and evaluation of novel ethambutol analogues. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1607-1611.	2.2	55
133	Pharmacokinetically-Guided Lead Optimization of Nitrofuranylamide Anti-Tuberculosis Agents. AAPS Journal, 2008, 10, 157-165.	4.4	34
134	N-Substituted 3-Acetyltetramic Acid Derivatives as Antibacterial Agents. Journal of Medicinal Chemistry, 2008, 51, 1487-1491.	6.4	42
135	Synthesis and Structure of Mycolactone E Isolated from Frog Mycobacterium. Organic Letters, 2008, 10, 5385-5388.	4.6	29
136	A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. Journal of Antimicrobial Chemotherapy, 2008, 62, 1037-1045.	3.0	94
137	A rapid approach to lipid profiling of mycobacteria using 2D HSQC NMR maps. Journal of Lipid Research, 2008, 49, 455-463.	4.2	34
138	Production of White Colonies on CHROMagar Candida Medium by Members of the Candida glabrata Clade and Other Species with Overlapping Phenotypic Traits. Journal of Clinical Microbiology, 2008, 46, 3498-3500.	3.9	29
139	Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs. Current Medicinal Chemistry, 2008, 15, 809-825.	2.4	34
140	First Cultivation and Characterization of Mycobacterium ulcerans from the Environment. PLoS Neglected Tropical Diseases, 2008, 2, e178.	3.0	175
141	Nitrofurans as Novel Anti-tuberculosis Agents: Identification, Development and Evaluation. Current Topics in Medicinal Chemistry, 2007, 7, 509-526.	2.1	39
142	Topology and Active Site of PlsY. Journal of Biological Chemistry, 2007, 282, 11339-11346.	3.4	34
143	Solid-Phase Synthesis of a Thymidinyl Dipeptide Urea Library. ACS Combinatorial Science, 2007, 9, 370-385.	3.3	17
144	Crystal Structure of the Anthrax Drug Target, Bacillus anthracis Dihydrofolate Reductase. Journal of Medicinal Chemistry, 2007, 50, 4374-4381.	6.4	26

#	Article	IF	Citations
145	Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6638-6642.	2.2	83
146	Solid-phase synthesis and biological evaluation of a uridinyl branched peptide urea library. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6899-6904.	2.2	29
147	Chemical Knockout of Pantothenate Kinase Reveals the Metabolic and Genetic Program Responsible for Hepatic Coenzyme A Homeostasis. Chemistry and Biology, 2007, 14, 291-302.	6.0	105
148	Acyl-Phosphates Initiate Membrane Phospholipid Synthesis in Gram-Positive Pathogens. Molecular Cell, 2006, 23, 765-772.	9.7	147
149	Monocyte and Macrophage Activation by Lipoteichoic Acid Is Independent of Alanine and Is Potentiated by Hemoglobin. Journal of Immunology, 2006, 176, 5567-5576.	0.8	19
150	Structureâ€“activity relationships and enzyme inhibition of pantothenamide-type pantothenate kinase inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 1007-1020.	3.0	61
151	Synthesis of new and potent analogues of anti-tuberculosis agent 5-nitro-furan-2-carboxylic acid 4-(4-benzyl-piperazin-1-yl)-benzylamide with improved bioavailability. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2584-2589.	2.2	44
152	Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. Molecular Cancer Therapeutics, 2006, 5, 1577-1584.	4.1	7
153	Globally Distributed Mycobacterial Fish Pathogens Produce a Novel Plasmid-Encoded Toxic Macrolide, Mycolactone F. Infection and Immunity, 2006, 74, 6037-6045.	2.2	120
154	Discovery of non-carbohydrate inhibitors of aminoglycoside-modifying enzymes. Bioorganic and Medicinal Chemistry, 2005, 13, 6252-6263.	3.0	51
155	Solid-phase synthesis development of a thymidinyl and 2â€²-deoxyuridinyl Ugi library for anti-bacterial agent screening. Tetrahedron Letters, 2005, 46, 8497-8501.	1.4	11
156	Genome-wide expression profiling of the response to ciclopirox olamine in Candida albicans. Journal of Antimicrobial Chemotherapy, 2005, 55, 655-662.	3.0	54
157	A Pantothenate Kinase from Staphylococcus aureus Refractory to Feedback Regulation by Coenzyme A. Journal of Biological Chemistry, 2005, 280, 3314-3322.	3.4	85
158	Genome-Wide Expression Profiling of the Response to Azole, Polyene, Echinocandin, and Pyrimidine Antifungal Agents in Candida albicans. Antimicrobial Agents and Chemotherapy, 2005, 49, 2226-2236.	3.2	316
159	A Newly Discovered Mycobacterial Pathogen Isolated from Laboratory Colonies of Xenopus Species with Lethal Infections Produces a Novel Form of Mycolactone, the Mycobacterium ulcerans Macrolide Toxin. Infection and Immunity, 2005, 73, 3307-3312.	2.2	110
160	Methods for Acquisition and Assignment of Multidimensional High-Resolution Magic Angle Spinning NMR of Whole Cell Bacteria. Analytical Chemistry, 2005, 77, 5785-5792.	6.5	32
161	Synthesis and Evaluation of Cyclic Secondary Amine Substituted Phenyl and Benzyl Nitrofuranyl Amides as Novel Antituberculosis Agents. Journal of Medicinal Chemistry, 2005, 48, 8261-8269.	6.4	91
162	Acyl Carrier Protein Is a Cellular Target for the Antibacterial Action of the Pantothenamide Class of Pantothenate Antimetabolites. Journal of Biological Chemistry, 2004, 279, 50969-50975.	3.4	76

#	Article	IF	Citations
163	Analysis of Mycobacterium Species for the Presence of a Macrolide Toxin, Mycolactone. Infection and Immunity, 2004, 72, 123-132.	2.2	17
164	Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1345-1349.	7.1	345
165	The Structure of the Pantothenate KinaseÂ·ADPÂ·Pantothenate Ternary Complex Reveals the Relationship between the Binding Sites for Substrate, Allosteric Regulator, and Antimetabolites. Journal of Biological Chemistry, 2004, 279, 35622-35629.	3.4	47
166	Crystal Structure of 7,8-Dihydropteroate Synthase from Bacillus anthracis. Structure, 2004, 12, 1705-1717.	3.3	97
167	Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents. Journal of Medicinal Chemistry, 2004, 47, 5276-5283.	6.4	81
168	Rapid structural characterization of the arabinogalactan and lipoarabinomannan in live mycobacterial cells using 2D and 3D HR-MAS NMR: structural changes in the arabinan due to ethambutol treatment and gene mutation are observed. Glycobiology, 2004, 15, 139-151.	2.5	55
169	Discovery of Novel Selective Inhibitors of Human Intestinal Carboxylesterase for the Amelioration of Irinotecan-Induced Diarrhea: Synthesis, Quantitative Structure-Activity Relationship Analysis, and Biological Activity. Molecular Pharmacology, 2004, 65, 1336-1343.	2.3	91
170	Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application. Molecular Cancer Therapeutics, 2004, 3, 903-9.	4.1	15
171	Novel Inhibitors of an Emerging Target in Mycobacterium tuberculosis; Substituted Thiazolidinones as Inhibitors of dTDP-Rhamnose Synthesis.. ChemInform, 2003, 34, no.	0.0	0
172	Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3227-3230.	2.2	151
173	Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolism. Bioorganic and Medicinal Chemistry, 2003, 11, 3237-3244.	3.0	10
174	Combinatorial Lead Optimization of [1,2]-Diamines Based on Ethambutol as Potential Antituberculosis Preclinical Candidates. ACS Combinatorial Science, 2003, 5, 172-187.	3.3	205
175	Heterogeneity of Mycolactones Produced by Clinical Isolates of Mycobacterium ulcerans : Implications for Virulence. Infection and Immunity, 2003, 71, 774-783.	2.2	156
176	Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. Molecular Cancer Therapeutics, 2003, 2, 1171-81.	4.1	11
177	Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Molecular Microbiology, 2000, 38, 514-525.	2.5	134
178	Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochemical Pharmacology, 2000, 59, 221-231.	4.4	124
179	An approach to combinatorial library generation of galactofuranose mimics as potential inhibitors of mycobacterial cell wall biosynthesis: Synthesis of a peptidomimetic of uridine 5â€²-diphosphogalactofuranose (UDP-Galf). Tetrahedron Letters, 1999, 40, 8689-8692.	1.4	50
180	Mycolactone: A Polyketide Toxin from Mycobacterium ulcerans Required for Virulence. Science, 1999, 283, 854-857.	12.6	602

#	Article	IF	Citations
181	Synthesis of Î²-D-arabinofuranosyl-1-monophosphoryl polyprenols: Examination of their function as mycobacterial arabinosyl transferase donors. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 951-954.	2.2	34
182	Mechanisms involved in the intrinsic isoniazid resistance ofMycobacterium avium. Molecular Microbiology, 1998, 27, 1223-1233.	2.5	76
183	Mycolic acids: structure, biosynthesis and physiological functions. Progress in Lipid Research, 1998, 37, 143-179.	11.6	504
184	Mycobacterial arabinan biosynthesis: the use of synthetic arabinoside acceptors in the development of an arabinosyl transfer assay. Glycobiology, 1997, 7, 1121-1128.	2.5	86
185	Mycolic acid biosynthesis: definition and targeting of the Claisen condensation step. Lipids and Lipid Metabolism, 1997, 1346, 275-284.	2.6	22
186	Characterization of the in vitro synthesized arabinan of mycobacterial cell walls. Biochimica Et Biophysica Acta - General Subjects, 1997, 1335, 231-234.	2.4	32
187	Inhibition of UDP-Gal Mutase and Mycobacterial Galactan Biosynthesis by Pyrrolidine Analogues of Galactofuranose. Tetrahedron Letters, 1997, 38, 6733-6736.	1.4	112
188	Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrobial Agents and Chemotherapy, 1996, 40, 2813-2819.	3.2	151
189	Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 6630-6634.	7.1	190
190	Synthesis of the Arabinose Donor .beta.-D-Arabinofuranosyl-1-monophosphoryldecaprenol, Development of a Basic Arabinosyl-Transferase Assay, and Identification of Ethambutol as an Arabinosyl Transferase Inhibitor. Journal of the American Chemical Society, 1995, 117, 11829-11832.	13.7	135
191	Identification of the apparent carrier in mycolic acid synthesis.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 12735-12739.	7.1	91